Objectives

After participating in this educational activity, attendees should be able to:

1| Summarize pathophysiology, epidemiology, presentation, and risks associated with atypical hemolytic uremic syndrome (aHUS) 
2| Differentiate aHUS from other thrombotic microangiopathies (TMAs) 
3| Review literature for the treatment and prevention of aHUS 
4| Discuss eculizumab (Soliris) and ravulizumab (Ultomiris) 
5| Apply this information to a patient case 
 

Faculty

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Pharmacists
Baystate Health designates this activity for a maximum of 1.0 contact hours (s) for pharmacists. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.